{"id":"NCT05707351","sponsor":"Takeda","briefTitle":"A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A","officialTitle":"A Phase 3, Prospective, Multicenter, Open-label Study of Efficacy, Safety, and Pharmacokinetics of PEGylated Recombinant Factor VIII (ADYNOVATE) Administered for Prophylaxis and Treatment of Bleeding in Chinese Previously Treated Patients With Severe Hemophilia A (FVIII <1%)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2023-03-27","primaryCompletion":"2024-09-05","completion":"2024-09-05","firstPosted":"2023-01-31","resultsPosted":"2025-05-01","lastUpdate":"2025-05-01"},"enrollment":37,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hemophilia A"],"interventions":[{"type":"BIOLOGICAL","name":"Adynovate","otherNames":["Antihemophilic Factor (recombinant) PEGylated, Rurioctocog Alfa Pegol"]}],"arms":[{"label":"Adynovate 45±5 IU/kg","type":"EXPERIMENTAL"}],"summary":"The main aim of the study is to determine how well Adynovate works to decrease bleeding in previously treated Chinese men and boys with severe hemophilia A when given prophylactically.\n\nParticipants will be treated with Adynovate twice a week for 26 weeks or until participants have received 50 days of treatment with Adynovate (whichever takes longer). Participants will need to visit their study clinic several times during their participation.","primaryOutcome":{"measure":"Total Annualized Bleeding Rates (ABR)","timeFrame":"Baseline through study completion or ≥50 EDs whichever occurred last (approximately 28 weeks)","effectByArm":[{"arm":"Adynovate","deltaMin":4.1,"sd":13.61}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":12,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/46da5667215042fa?idFilter=%5B%22TAK-660-3001%22%5D"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":37},"commonTop":["Arthralgia","Diarrhoea","Alanine aminotransferase increased","Aspartate aminotransferase increased","Hyperlipidaemia"]}}